All In Biotech

Drug Trial Radar · NCT01423188

The Study of Quantitative Serial Trends in Lipids With ApolpoproteinA-I Stimulation

Phase IIb Multi-center, Double-blind, Randomized, Parallel Group, Placebo Controlled Clinical Trial for the Assessment of Lipid Trends and Safety of RVX000222 in Statin Treated Subjects With Low Baseline HDL-C Concentrations

Last checked: Nov 19, 2026Latest source record: Sep 20, 2012 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 176 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

176

Actual

Start

Aug 2011

Primary completion

Jun 2012

Study completion Aug 2012

Sponsor

Lead sponsor
Resverlogix CorpIndustry
Sponsor type
Industry
Collaborators
The Cleveland Clinic
First posted
Aug 25, 2011

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is designed to provide an assessment of the change in baseline lipid parameters with RVX000222 after 12 weeks and 24 weeks of treatment when given in addition to optimized statin background therapy in subjects with low baseline HDL-C.

Conditions

  • Coronary Artery Disease
  • Dyslipidemia

Interventions

  • RVX000222Drug

    capsule, 200 mg, administer with food, 100 mg twice daily 10-12 hrs apart, 24 weeks

  • Placebo RVX000222Drug

    capsule, administer with food, twice daily 10-12 hrs apart, 24 weeks

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The percent change in HDL-C from baseline to 24 weeks for RVX000222 200 mg daily compared to placeboTime frame: 24 weeks

Locations

25 sites in 1 country. Site status is shown where the registry gives one.

  • Site not named

    Bloemfontein, South Africa

  • Site not named

    Cape Town, South Africa

  • Site not named

    Cape Town, South Africa

  • Site not named

    Johannesburg, South Africa

  • Site not named

    Western Cape, South Africa

  • Site not named

    East Burger Street, Bloemfontein, South Africa

  • Site not named

    Westdene, Bloemfontein, South Africa

  • Site not named

    Goodwood, Cape Town, South Africa

  • Site not named

    Kraaifontein, Cape Town, South Africa

  • Site not named

    Pinelands, Cape Town, South Africa

  • Site not named

    Chatsworth, Durban, South Africa

  • Site not named

    KwaKhangela, Durban, South Africa

  • Site not named

    Merebank, Durban, South Africa

  • Site not named

    Sydenham, Durban, South Africa

  • Site not named

    Tongaat, Durban, South Africa

  • Site not named

    Umhlanga, Durban, South Africa

  • Site not named

    Lenasia, Johannesburg, South Africa

  • Site not named

    Halfway House, Midrand, South Africa

  • Site not named

    Die Wilgers, Pretoria, South Africa

  • Site not named

    Eloffsdal, Pretoria, South Africa

  • Site not named

    Kuils River, Western Cape, South Africa

  • Site not named

    Parow, Western Cape, South Africa

  • Site not named

    Somerset West, Western Cape, South Africa

  • Site not named

    Stellenbosch, Western Cape, South Africa

  • Site not named

    Worcester, Western Cape, South Africa

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.